尿酸脑保护作用跨越性别、年龄和合并症:多中心临床前试验
在中风临床前评估网络(SPAN)的多中心试验中,710只动物随机接受静脉尿酸(16 mg/kg)或生理盐水,687只纳入分析(尿酸组458只,对照组229只)。尿酸组第30天主要功能结局更优(概率0.56,95%CI 0.52-0.60,P=0.006),第7天转角试验指数更优(概率0.55,95%CI 0.5-0.59,P=0.035),第30天生存率更高(HR 1.41,95%CI 1.08-1.83,P=0.011),且获益在不同物种、性别、年龄和合并症中均保留。
要点
- 尿酸组第30天改良转角试验指数优于对照组(概率0.56 vs 0.52-0.60,P=0.006)。
- 尿酸组第30天生存率高于对照组(HR 1.41,95%CI 1.08-1.83,P=0.011)。
- 功能结局和生存获益在不同物种、性别、年龄和合并症中均保留。
核心结论
- 尿酸在关键相关生物学变量中提供缺血性卒中脑保护,是值得在人体临床试验中进一步测试的有前景干预措施。
研究设计与样本
- SPAN网络的多中心临床前试验,710只动物随机接受静脉尿酸(16 mg/kg)或静脉生理盐水,687只纳入改良意向性分析(尿酸组458只,对照组229只)。
- 药物在短暂大脑中动脉线栓闭塞再灌注期间给药,主要结局为卒中后第30天改良转角试验指数。
主要发现
- 尿酸组第30天主要功能结局优于对照组(概率0.56,95%CI 0.52-0.60,P=0.006)。
- 尿酸组第7天转角试验指数优于对照组(概率0.55,95%CI 0.5-0.59,P=0.035)。
- 尿酸组第30天生存率高于对照组(HR 1.41,95%CI 1.08-1.83,P=0.011)。
- 第2天和第30天脑形态计量学在治疗组间相当。
- 功能结局和生存获益在不同物种、性别、年龄和合并症中均保留。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Past failures in translating stroke cerebroprotection provoked calls for a more rigorous methodological approach, leading to the stroke preclinical assessment network SPAN (Stroke Preclinical Assessment Network), where uric acid (UA) treatment exceeded a prespecified efficacy boundary for the primary functional outcome. Still, successful translation to humans requires confirmation of the effect of UA across key biological variables relevant to patients with stroke. METHODS: We measured the effects of intravenous UA treatment (16 mg/kg) versus intravenous saline in groups of animals enrolled in the SPAN network with diverse comorbidities, sex, and age. The masked study drug or placebo was administered during reperfusion in rodents undergoing a transient middle cerebral artery filament occlusion. The primary outcome was the modified corner test index at day 30 poststroke, and numerous secondary outcomes were collected. A modified intention-to-treat population was used in the analysis. We tested for any interactions with sex, age, and comorbidities (obesity-induced hyperglycemia and hypertension). RESULTS: In total, 710 animals were randomized to receive either intravenous UA or saline. After accounting for procedural dropouts and exclusions from treatment, a total of 687 animals were qualified and analyzed, including 458 assigned to UA and 229 to intravenous saline control. UA-treated animals exhibited a better primary functional outcome at day 30 (probability, 0.56 [95% CI, 0.52-0.60]; P=0.006). UA-treated animals also had a better corner test index at day 7 (probability, 0.55 [95% CI, 0.5-0.59]; P=0.035) and a higher survival rate at day 30 (hazard ratio, 1.41 [95% CI, 1.08-1.83]; P=0.011). Brain morphometry at day 2 and 30 was comparable between the treatment groups. The improved functional outcome and survival in UA-treated animals were preserved across different species, sexes, ages, and comorbidities. CONCLUSIONS: UA provides ischemic stroke cerebroprotection across key relevant biological variables, making it a promising intervention to be further tested in human clinical trials.
引用
- Patel RB, Kumskova M, Kodali H, et al. Uric Acid Stroke Cerebroprotection Transcended Sex, Age, and Comorbidities in a Multicenter Preclinical Trial. Stroke. 2025. PMID: 40091742. doi:10.1161/STROKEAHA.124.048748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。